Lv4
780 积分 2022-08-10 加入
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
2天前
已完结
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
2天前
已关闭
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
8天前
已完结
The efficacy and safety of cadonilimab after first anti-PD-1 failure in the treatment of recurrent endometrial and cervical carcinoma: A retrospective, real-world study
1个月前
已完结
Baseline, Early Changes, and Residual Albuminuria: Post-hoc Analysis of a Clinical Trial of Dapagliflozin in Chronic Kidney Disease
2个月前
已关闭
baseline, early changes, and residual albuminuria: post-hoc analysis of a clinical trial of dapagliflozin in chronic kidney disease
2个月前
已关闭
A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy
2个月前
已完结
Quantifying Duration of Proteinuria Remission and Association with Clinical Outcome in IgA Nephropathy
3个月前
已完结
Consensus statement on the management of hyperkalaemia-An Asia-Pacific perspective
4个月前
已完结
Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy
4个月前
已完结
皖公网安备34019202002308
